Other studies have evaluated the aromatase inhibitor letrozole in combination with everolimus and have demonstrated responses in patients with metastatic endometrial carcinoma (trial registration ID: NCT01068249) [9] and breast cancer (trial registration ID: NCT00107016) [10]. Here, CYP19A1 is linked to breast cancer.